Login to Your Account



Regulatory NEWS
When it comes to the compounding of drugs, the one thing everyone agrees on is that something needs to be done to ensure the safety of the products. But how to do that is another matter.
Washington Roundup
Despite an increase in transparency and collaboration in China, the safety of drugs and other products imported from the country remains a concern in the U.S. Currently, the FDA has 74 active import alerts, many of which involve Chinese companies, and nine countrywide alerts pertaining to China.
The backlog of new applications is growing again at the Patent and Trademark Office (PTO), thanks in part to sequestration. Using new fees included in the 2011 patent reform to hire and train more examiners, the office had been plowing through the backlog, reducing the pile of nearly 722,000 applications in December 2010 to about 593,000 in February.
More Regulatory Headlines

Cast Your Vote

What is biopharma’s biggest need on the regulatory front?: